文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

古脂质体作为癌症疫苗的自佐剂递送系统。

Archaeosomes as self-adjuvanting delivery systems for cancer vaccines.

作者信息

Krishnan Lakshmi, Dennis Sprott G

出版信息

J Drug Target. 2003;11(8-10):515-24. doi: 10.1080/10611860410001670044.


DOI:10.1080/10611860410001670044
PMID:15203920
Abstract

Archaeal ether glycerolipid vesicles (archaeosomes) efficiently deliver exogenous antigen for induction of humoral and cell-mediated immunity. Because induction of CD8 cytotoxic T cells is critical for protective vaccination against tumors, we compared the ability of various archaeosome lipid compositions to evoke a strong CD8 CTL response to entrapped antigen. Subcutaneous immunization of mice with ovalbumin (OVA) entrapped in all archaeosome lipid compositions evoked a primary (day 10) splenic CTL response indicating processing for MHC class I presentation. Interestingly, several polar lipid compositions from halophilic archaea were very potent to adjuvant this early CTL response. Despite this, the lytic units reduced substantially by weeks 6-7. More importantly, at >50 weeks, only Methanobrevibacter smithii and Thermoplasma acidophilum both rich in bipolar membrane-spanning caldarchaeols, demonstrated recall memory CTLs. Immunization of mice with OVA entrapped in M. smithii, Halobacterium salinarum or T. acidophilum vesicles provided prophylactic protection against challenge with OVA-expressing solid tumors at 6 weeks. Even a dose of 3 microg OVA in archaeosomes significantly delayed tumor growth. Tumor protection was also noted in a therapeutic design wherein OVA-archaeosomes were injected concurrent with the tumor challenge. Interestingly, antigen-free T. acidophilum but not antigen-free H. salinarum archaeosomes provided innate therapeutic protection. Vaccination with a CTL peptide epitope from the melanoma differentiation antigen, tyrosinase-related protein 2, in archaeosomes induced a protective CD8 response against B16OVA metastasis, indicating potential for targeting self, tumor antigens. Thus, lipid structural properties of archaea may differentially modulate primary, long-term and/or innate immunity, impacting adjuvant choice for vaccine design.

摘要

古菌醚甘油脂质体(嗜烷颗粒)能有效递送外源性抗原以诱导体液免疫和细胞介导的免疫。由于诱导CD8细胞毒性T细胞对于肿瘤的保护性疫苗接种至关重要,我们比较了各种嗜烷颗粒脂质成分引发针对包裹抗原的强烈CD8细胞毒性T淋巴细胞(CTL)反应的能力。用包裹在所有嗜烷颗粒脂质成分中的卵清蛋白(OVA)对小鼠进行皮下免疫,引发了初级(第10天)脾脏CTL反应,表明其可进行MHC I类呈递的加工处理。有趣的是,来自嗜盐古菌的几种极性脂质成分对辅助这种早期CTL反应非常有效。尽管如此,到第6 - 7周时,裂解单位大幅减少。更重要的是,在超过50周时,只有富含双极跨膜钙古菌素的史密斯甲烷短杆菌和嗜酸嗜热放线菌表现出记忆CTL。用包裹在史密斯甲烷短杆菌、盐生盐杆菌或嗜酸嗜热放线菌囊泡中的OVA对小鼠进行免疫,在6周时可提供针对表达OVA的实体瘤攻击的预防性保护。即使在嗜烷颗粒中3微克OVA的剂量也能显著延迟肿瘤生长。在一种治疗设计中也观察到了肿瘤保护作用,即OVA - 嗜烷颗粒与肿瘤攻击同时注射。有趣的是,不含抗原的嗜酸嗜热放线菌囊泡而非不含抗原的盐生盐杆菌囊泡提供了先天性治疗保护。用来自黑色素瘤分化抗原酪氨酸酶相关蛋白2的CTL肽表位在嗜烷颗粒中进行疫苗接种,诱导了针对B16OVA转移的保护性CD8反应,表明靶向自身肿瘤抗原的潜力。因此,古菌的脂质结构特性可能会不同程度地调节初级、长期和/或先天性免疫,影响疫苗设计中佐剂的选择。

相似文献

[1]
Archaeosomes as self-adjuvanting delivery systems for cancer vaccines.

J Drug Target. 2003

[2]
Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.

Cancer Res. 2003-5-15

[3]
Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.

J Immunol. 2000-11-1

[4]
Safety of archaeosome adjuvants evaluated in a mouse model.

J Liposome Res. 2002-11

[5]
Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class I cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing.

J Immunol. 2004-7-1

[6]
Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.

Vaccine. 2007-12-12

[7]
Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants.

Hum Vaccin Immunother. 2018-1-30

[8]
Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity.

Hum Vaccin Immunother. 2017-5-24

[9]
Archaeosomes varying in lipid composition differ in receptor-mediated endocytosis and differentially adjuvant immune responses to entrapped antigen.

Archaea. 2003-10

[10]
Archaeosome immunostimulatory vaccine delivery system.

Curr Drug Deliv. 2005-10

引用本文的文献

[1]
Doxorubicin loaded thermostable nanoarchaeosomes: a next-generation drug carrier for breast cancer therapeutics.

Nanoscale Adv. 2024-1-2

[2]
Quantitative Analysis of Core Lipid Production in at Different Scales.

Bioengineering (Basel). 2022-4-10

[3]
Development of thermostable vaccine adjuvants.

Expert Rev Vaccines. 2021-5

[4]
Formulation and delivery of vaccines: Ongoing challenges for animal management.

J Pharm Bioallied Sci. 2012-10

[5]
Synthetic archaeosome vaccines containing triglycosylarchaeols can provide additive and long-lasting immune responses that are enhanced by archaetidylserine.

Archaea. 2012-9-30

[6]
Nanoparticle delivery systems in cancer vaccines.

Pharm Res. 2010-8-19

[7]
Archaeosomes made of Halorubrum tebenquichense total polar lipids: a new source of adjuvancy.

BMC Biotechnol. 2009-8-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索